Bio-Techne is a life-science tools and diagnostics supplier pursuing growth across research, spatial biology, cell and gene therapy, and precision diagnostics; its standalone strategy has centered on expanding differentiated products and adjacent markets through innovation and acquisitions. Merck’s proposed purchase would fold that platform into a much larger life-science organization for $73 per share in cash, or roughly $11.3 billion of enterprise value.
The shareholder hurdle is cleared, but this is a milestone—not a completed deal. Bio-Techne said shareholders approved and adopted the merger agreement. 〔0〕 The Hart-Scott-Rodino waiting period also expired on September 18, 2026. 〔1〕 That removes two important process risks, but the vote and antitrust clearance were already expected parts of the announced transaction, so the filing mainly reduces execution uncertainty rather than changing the strategic story.
The remaining risk is concentrated in regulatory clearance and closing execution. The company still expects completion by late 2026 or early 2027, subject to customary conditions and remaining required approvals. 〔2〕 The filing therefore advances the deal toward completion, while leaving the core timing and integration questions unresolved.
Bottom line: This is a clean approval milestone for an already-announced acquisition, not a new strategic surprise. It makes Merck’s purchase of Bio-Techne more executable, but the transaction still depends on remaining regulatory sign-offs and closing conditions.
Read the original 8-K on SEC EDGAR ↗